Model validity range in multicentre clinical trials

被引:0
|
作者
Dragalin, V [1 ]
Fedorov, VV [1 ]
机构
[1] GlaxoSmithKline, King Of Prussia, PA 19406 USA
关键词
combined response to treatment; model validity range; multicentre trial;
D O I
暂无
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
Analyses of multicentre trials consider the estimated treatment effect differences of the individual centres and combine them into an estimate of the overall treatment effect. There has been much debate in the literature concerning the best way to combine these treatment effect differences. We emphasize that first of all one should define the combined response to treatment (CRT), the object that has to be estimated from the results of a multicentre clinical trial. Having the defined target in mind, the least squares estimators of the CRT under three possible models of increasing complexity for multicentre data axe derived. We compare these estimators in terms of their mean squared errors. It is shown that the choice of CRT determines not only the best estimator, but also the allocation of patients among the centres that minimizes the MSE.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [21] Validity of a risk scale for clinical trials
    Peyrouzet, H.
    Gimbert, A.
    Boury, F.
    Moore, N.
    Boussuge-Roze, J.
    Miremont-Salame, G.
    Haramburu, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 104 - 104
  • [22] Assessing clinical utility and clinical validity of biomarkers in clinical trials
    Caldas, C.
    BREAST, 2023, 68 : S3 - S3
  • [23] Handling dropout and clustering in longitudinal multicentre clinical trials
    Del Bianco, P.
    Borgoni, R.
    STATISTICAL MODELLING, 2006, 6 (02) : 141 - 157
  • [24] RANGE OF VALIDITY OF THE HYDRODYNAMIC SCALING MODEL
    PHILLIES, GDJ
    JOURNAL OF PHYSICAL CHEMISTRY, 1992, 96 (24): : 10061 - 10066
  • [25] Optimal design and the model validity range
    Fedorov, VV
    Montepiedra, G
    Nachtsheim, CJ
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1998, 72 (1-2) : 215 - 227
  • [26] The Validity of Setting Error Rates in Clinical Trials
    Achison, Marcus
    McKenzie, Andrew N.
    Adamson, Simon B.
    Haenicke, Stephanie
    Georgiev, Vesselin
    Rocha, Joana
    Lahnsteiner, Eva
    McKenzie, Emma J.
    TRIALS, 2019, 20
  • [27] Validity of block randomized clinical trials - Reply
    Whitcomb, Brian W.
    Schisterman, Enrique F.
    Ruopp, Marcus D.
    Collins, Tara C.
    FERTILITY AND STERILITY, 2008, 89 (05) : 1281 - 1282
  • [28] VALIDITY OF NEGATIVE RANDOMIZED CLINICAL-TRIALS
    FREIMAN, JA
    SMITH, H
    CHALMERS, TC
    CLINICAL RESEARCH, 1977, 25 (03): : A512 - A512
  • [29] Validity of composite end points in clinical trials
    Montori, VM
    Permanyer-Miralda, G
    Ferreira-González, I
    Busse, JW
    Pacheco-Huergo, V
    Bryant, D
    Alonso, J
    Akl, EA
    Domingo-Salvany, A
    Mills, E
    Wu, P
    Schünemann, HJ
    Jaeschke, R
    Guyatt, GH
    BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7491): : 594 - 596
  • [30] TIME IN RANGE AS AN OUTCOME IN CLINICAL TRIALS
    Beck, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A2 - A2